Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

Hospital for Special Surgery (HSS) plans to host a two-day international Osteoarthritis Summit in June 2011. The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together, for the first time, a truly comprehensive multidisciplinary group of world renowned scientists, thought-leaders and industry representatives from the United …

]Arthritis study: People aged 50 and older with hip or knee arthritis sought for physiotherapy studies. Details: fmcmanus @unimelb.edu.au or 83440426.

Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced results of preclinical studies demonstrating that its clinical candidate, AVL-292, potently inhibits B cell receptor signaling, and demonstrates efficacy in a rodent model of rheumatoid arthritis. These new data were presented Saturday, June 26 ...

The Arthritis Foundation has begun a new pilot program designed to improve the early diagnosis of rheumatoid arthritis and to decrease the number of people with inflammatory arthritis who become disabled due to the lack of early diagnosis and treatment.